CanSino Biologics Inc. (CASBF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CanSino Biologics Inc. (CASBF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0.
Ultimo analisis: 16 mar 2026CanSino Biologics Inc. (CASBF) Resumen de Asistencia Médica y Tuberías
CanSino Biologics Inc. is a Chinese vaccine company focused on developing and commercializing innovative vaccines, including its COVID-19 vaccine, Convidecia, and vaccines for other infectious diseases like Ebola and meningitis, positioning itself within China's growing biopharmaceutical market amidst competition from both domestic and international players.
Tesis de Inversión
CanSino Biologics presents a mixed investment case. Its COVID-19 vaccine, Convidecia, provided significant revenue during the pandemic, but future growth hinges on its pipeline of other vaccines. The company's high P/E ratio of 736.81 suggests that investors have high expectations for future earnings growth. CanSino's success depends on navigating regulatory approvals in China, successfully commercializing its pipeline products, and maintaining a competitive edge in the vaccine market. The company's ongoing research and development efforts, particularly in pneumococcal and tuberculosis vaccines, represent potential growth catalysts. However, the company faces competition from established global vaccine manufacturers and domestic players.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $1.35 billion indicates CanSino Biologics' current valuation in the market.
- A P/E ratio of 736.81 suggests that the company's stock price is high relative to its earnings.
- Gross margin of 100.0% reflects efficient vaccine production and sales.
- Profit margin of 2.6% indicates the percentage of revenue that turns into profit.
- Beta of 1.32 suggests the stock is more volatile than the market.
Competidores y Pares
Fortalezas
- Innovative vaccine technologies.
- Strong manufacturing capabilities.
- Established presence in the Chinese market.
- Successful development of COVID-19 vaccine.
Debilidades
- High P/E ratio.
- Reliance on the Chinese market.
- Limited international presence.
- Dependence on regulatory approvals.
Catalizadores
- Upcoming: Regulatory approvals for new vaccine candidates in China.
- Ongoing: Expansion of manufacturing capacity to meet growing demand.
- Ongoing: Progress in clinical trials for pneumococcal and tuberculosis vaccines.
- Upcoming: Potential partnerships with international organizations for global distribution.
- Ongoing: Continued research and development of innovative vaccine technologies.
Riesgos
- Potential: Competition from established vaccine manufacturers.
- Ongoing: Regulatory challenges and delays in approvals.
- Potential: Fluctuations in demand for vaccines.
- Potential: Patent expirations and intellectual property disputes.
- Ongoing: Dependence on the Chinese market.
Oportunidades de crecimiento
- Expansion of Vaccine Portfolio: CanSino has an opportunity to expand its vaccine portfolio beyond COVID-19. The development and commercialization of vaccines for diseases like pneumococcal disease (PBPV and PCV13i) and tuberculosis (TB Booster) can drive future revenue growth. The global pneumococcal vaccine market is projected to reach $12.9 billion by 2027, while the TB vaccine market is expected to grow as well, driven by the need for more effective TB prevention strategies.
- International Market Expansion: While currently focused on the Chinese market, CanSino can explore opportunities to expand its reach internationally, particularly in developing countries with unmet needs for vaccines. This expansion could involve partnerships with local distributors or establishing manufacturing facilities in other regions. The global vaccine market is expected to reach $90 billion by 2025, presenting significant opportunities for companies with innovative vaccine technologies.
- Development of Combination Vaccines: CanSino is developing combination vaccines like the DTcP-Hib Combo vaccine, which can provide protection against multiple diseases with a single injection. Combination vaccines can improve vaccination rates and reduce healthcare costs. The global market for combination vaccines is growing, driven by the convenience and cost-effectiveness of these products.
- Focus on Innovative Vaccine Technologies: CanSino's use of adenovirus vector technology for its COVID-19 vaccine demonstrates its commitment to innovation. The company can continue to invest in research and development of new vaccine technologies to improve vaccine efficacy, safety, and delivery. This includes exploring mRNA vaccine technology, which has shown promise in the development of COVID-19 vaccines.
- Partnerships and Collaborations: CanSino can leverage partnerships and collaborations with other pharmaceutical companies, research institutions, and government agencies to accelerate vaccine development and commercialization. These partnerships can provide access to new technologies, funding, and market expertise. Collaboration with international organizations like the WHO can also facilitate access to global markets.
Oportunidades
- Expansion of vaccine portfolio.
- International market expansion.
- Development of combination vaccines.
- Partnerships and collaborations.
Amenazas
- Competition from established vaccine manufacturers.
- Regulatory challenges.
- Patent expirations.
- Fluctuations in demand for vaccines.
Ventajas competitivas
- Proprietary vaccine technologies.
- Established manufacturing capabilities in China.
- Strong relationships with government agencies.
- First-mover advantage in certain vaccine markets in China.
Acerca de CASBF
CanSino Biologics Inc., founded in 2009 and headquartered in Tianjin, China, is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing vaccines. The company's initial focus was on developing vaccines for prevalent infectious diseases. A key milestone was the development of Ad5-EBOV, an Ebola virus vaccine. CanSino gained prominence during the COVID-19 pandemic with its development of Convidecia, a single-dose COVID-19 vaccine. The company also produces MCV2 and MCV4 vaccines for the prevention of N. meningitides. CanSino continues to expand its pipeline with vaccines in various stages of development, including DTcP vaccines for infants, Tdcp Adolescent and Adult vaccines, and PBPV, a serotype-independent protein-based pneumococcal vaccine. The company is also engaged in preclinical research for vaccines targeting diseases such as adenovirus, ZIKA virus, meningitis, shingles, and polio. CanSino's geographic focus is primarily within China, aligning with the country's national health priorities and market demands.
Qué hacen
- Develops vaccines for infectious diseases.
- Manufactures vaccines in China.
- Commercializes vaccines in the Chinese market.
- Focuses on vaccines for COVID-19, Ebola, and meningitis.
- Conducts clinical trials for new vaccine candidates.
- Engages in preclinical research for future vaccines.
Modelo de Negocio
- Develops proprietary vaccine technologies.
- Manufactures vaccines in its own facilities.
- Sells vaccines to government agencies and healthcare providers in China.
- Generates revenue through vaccine sales.
Contexto de la Industria
CanSino Biologics operates in the global vaccine market, which is characterized by increasing demand due to emerging infectious diseases and growing awareness of preventative healthcare. The market is dominated by established players like Pfizer and GSK, but also includes emerging companies like CanSino focusing on specific regional markets. The Chinese vaccine market is driven by government initiatives to improve public health and increase vaccine accessibility. The industry is subject to stringent regulatory requirements and requires significant investment in research and development.
Clientes Clave
- Government agencies responsible for public health.
- Hospitals and clinics.
- Vaccination centers.
- Individuals seeking vaccination.
Finanzas
Gráfico e información
Precio de la acción de CanSino Biologics Inc. (CASBF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para CASBF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CASBF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CASBF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CASBF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Xuefeng Yu
CEO
Xuefeng Yu is the CEO of CanSino Biologics Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on vaccine development and commercialization. He has been instrumental in guiding CanSino through its growth phase, overseeing the development of key vaccine candidates and establishing partnerships with research institutions and government agencies. His leadership is focused on driving innovation and expanding CanSino's presence in the global vaccine market.
Historial: Under Xuefeng Yu's leadership, CanSino Biologics has achieved significant milestones, including the development and approval of Convidecia, its COVID-19 vaccine. He has also overseen the expansion of CanSino's vaccine pipeline and the establishment of manufacturing facilities. His strategic decisions have positioned CanSino as a key player in the Chinese vaccine market.
Información del mercado OTC de CASBF
The OTC Other tier represents the lowest tier of the OTC market, indicating that CanSino Biologics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or that it may be unwilling or unable to meet those standards. Companies on this tier may have limited financial disclosure, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to less transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Financial Disclosure: The lack of transparency regarding CanSino Biologics' financial reporting makes it difficult for investors to assess the company's financial health and performance.
- Low Liquidity: The low trading volume associated with OTC Other stocks can make it challenging to buy or sell shares at desired prices.
- Regulatory Uncertainty: OTC Other companies are subject to fewer regulatory requirements than companies listed on major exchanges, which can increase the risk of fraud or mismanagement.
- Price Volatility: The limited liquidity and lack of information can lead to increased price volatility.
- Going Concern Risk: Companies on the OTC Other tier may face a higher risk of financial distress or bankruptcy.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and their track record.
- Check for any regulatory actions or legal proceedings against the company.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established vaccine development and manufacturing operations.
- Development and approval of COVID-19 vaccine.
- Partnerships with research institutions and government agencies.
- Focus on addressing public health needs in China.
Lo Que los Inversores Preguntan Sobre CanSino Biologics Inc. (CASBF)
¿Cuáles son los factores clave para evaluar CASBF?
Evaluar CASBF implica revisar los fundamentales, el consenso de analistas y los factores de riesgo. Fortaleza clave: Innovative vaccine technologies.. Riesgo principal a monitorear: Potential: Competition from established vaccine manufacturers.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CASBF?
El MoonshotScore califica a CASBF de 0 a 100 en salud financiera, impulso del mercado y factores de riesgo. Puntuaciones superiores a 70 indican calificaciones más altas, 50-70 moderadas y por debajo de 50 calificaciones más bajas. Se recalcula diariamente. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CASBF?
Los precios de CASBF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CASBF?
La cobertura de analistas para CASBF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CASBF?
Las categorías de riesgo para CASBF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established vaccine manufacturers.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CASBF?
La relación P/E para CASBF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CASBF sobrevalorada o infravalorada?
Determinar si CanSino Biologics Inc. (CASBF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CASBF?
CanSino Biologics Inc. (CASBF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.